India's Pharma Exports Face Compliance Challenges Amid Global Scrutiny
Compliance squeeze, global scrutiny redefine India’s $30 billion pharma export playbook
The Economic Times
Image: The Economic Times
India's pharmaceutical exports, valued at $30.47 billion in FY25, are facing rising compliance costs and global scrutiny, impacting especially micro, small, and medium enterprises (MSMEs). With over 60% of exports directed to regulated markets, the industry is shifting towards higher quality standards amidst increasing regulatory pressures.
- 01India's pharmaceutical exports grew to $30.47 billion in FY25, up from $20-21 billion pre-pandemic.
- 02Compliance costs have risen by 15-25% due to stricter global standards and increased scrutiny.
- 03MSMEs, accounting for 30-40% of production, are disproportionately affected by rising compliance costs.
- 04Consolidation in the pharma sector is likely as smaller firms struggle to meet compliance demands.
- 05Future growth will depend on regulatory trust and quality assurance rather than just price competitiveness.
Advertisement
In-Article Ad
India, known as the 'pharmacy of the world,' supplies nearly 20% of global generic volume and over 60% of vaccines. Its pharmaceutical exports have risen to $30.47 billion in FY25, reflecting a 9% annual growth. However, the industry faces significant challenges due to rising compliance costs, which have increased by 15-25% over the past few years due to stricter global regulations. This has particularly impacted micro, small, and medium enterprises (MSMEs), which account for a substantial portion of production but have a lower share in exports. Experts suggest that consolidation is likely as smaller firms struggle to adapt to these rising costs. The future of the sector hinges on maintaining high standards of quality and regulatory trust, as global buyers increasingly prioritize compliance over cost. The geopolitical landscape and evolving trade dynamics further complicate the situation, emphasizing the need for capability building and regulatory harmonization in trade agreements.
Advertisement
In-Article Ad
The rising compliance costs are straining the financial resources of MSMEs, potentially leading to consolidation in the sector. This could result in job losses and reduced market competition.
Advertisement
In-Article Ad
Reader Poll
How should India address rising compliance costs in the pharmaceutical sector?
Connecting to poll...
Read the original article
Visit the source for the complete story.